Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers

Liver International

Volumn 32, Issue 5, 2012, Pages 796-802

  Park, Hana ^a   Lee, Jung Min ^a,b   Seo, Ju Hee ^a   Kim, Hyon Suk ^a   Ahn, Sang Hoon ^a   Kim, Do Young ^a   Han, Kwang Hyub ^a   Chon, Chae Yoon ^a   Park, Jun Yong ^a  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

Chronic hepatitis B; Hepatitis B e antigen; Hepatitis surface antigen

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE CARRIER; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INACTIVE CARRIER; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; CARRIER STATE; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEROLOGIC TESTS; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION; YOUNG ADULT;

EID: 84859440095     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02693.x     Document Type: Article

References (27)

1. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
2. Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.
3. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
4. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
5. Lee KS. Management of Chronic Hepatitis B. Korean J Hepatol 2007; 13: 447-88.
6. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-8.
7. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-7.
8. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
9. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
10. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
11. Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53: 1486-93.
12. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-22.
13. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-13.
14. Chen CH, Lee CM, Wang JH, et al. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol 2004; 16: 1213-8.
15. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-90.
16. Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006; 44: 915-24.
17. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115: 217-22.
18. Kim HS, Han KH, Ahn SH, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10: 441-9.
19. Kim SU, Kim do Y, Park JY, et al. How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol 2010; 44: 66-71.
20. Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-41.
21. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
22. Rodella A, Galli C, Terlenghi L, et al. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006; 37: 206-12.
23. Galli C, Orlandini E, Penzo L, et al. What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology? J Med Virol 2008; 80: 974-9.
24. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-44.
25. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009; 14: 1183-8.
26. Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693-9.
27. Ikeda K, Arase Y, Saitoh S, et al. Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase. Am J Med 2006; 119: 977-85.